AXCOFARMA
ActiveSummary
AXCOFARMA has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €47,483 and a net result of €30,886. Equity is growing by about 7.4% per year across the filed financial years. Its solvency ranks better than 20% of 12,672 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
09-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
19-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
27-06
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
31-12
Financial
Highest result from 2018 to 2025net €77,458 ▲42.5%
Operating result €77,795, net result €77,458, both a record.
15-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
25-06
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
15-07
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
31-12
Financial
Back to profitnet €17,660
Net result €17,660 after one loss-making year.
28-08
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format · 28 days late
2018
27-08
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format · 27 days late
2017
30-08
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 19 annual accounts filed, the latest 10 are here; all 19 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.